8-K: Cytokinetics' Aficamten Data Shows Cardiac Improvement

Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting improved cardiac structure and function and a low incidence of atrial fibrillation.

Summary

• Additional data for aficamten was presented at the European Society of Cardiology Congress 2025 in Madrid, Spain.
• A pre-specified analysis from MAPLE-HCM showed aficamten improves cardiac structure and function compared to metoprolol, with simultaneous publication in the Journal of the American College of Cardiology.
• Aficamten was superior to metoprolol at improving measures of diastolic function and reducing the likelihood of mitral valve systolic anterior motion (SAM) and mitral valve leaflet-septal contact (all p<0.001).
• Patients treated with aficamten showed a significant decrease in maximal wall thickness (treatment corrected difference = -1.01 mm [95% CI -1.8 to -0.2, p=0.015]) compared to metoprolol.
• A Late Breaking Clinical Science presentation showed the annual incidence rate of new-onset atrial fibrillation (AF) with aficamten is 1.5% (4 out of 136 patients without prior AF), consistent with expected rates in HCM patients (HCM-AF: 3.6% per year) and healthy individuals (CHARGE-AF: 1.4% per year). This was simultaneously published in Heart Rhythm.
• Longer-term data from FOREST-HCM (mean follow-up 62 weeks, max 170 weeks, 352 patient-years exposure) showed sustained hemodynamic and clinical benefits, low incidence of new-onset AF (3 patients, 1%) and LVEF <50%.
• Aficamten treatment resulted in a significant reduction in Valsalva LVOT-G by Week 12 (resting LVOT-G = -40 mmHg, Valsalva LVOT-G = -56 mmHg; p<0.0001 for both), sustained for up to three years.
• 69% of patients at Week 12 (n=283) and 93% at Week 96 (n=44) reported a 1 New York Heart Association (NYHA) Functional Class improvement from baseline.
• Patients experienced a mean increase in KCCQ-CSS of 15 and 16 points (p<0.0001) at Week 12 and Week 96, respectively.
• Significant improvements were observed in NT-proBNP and high-sensitivity cardiac troponin I (both p<0.0001).
• An integrated safety analysis across REDWOOD-HCM, SEQUOIA-HCM, MAPLE-HCM, and FOREST-HCM (463 participants, almost 700 patient-years exposure) showed aficamten was well-tolerated with an adverse event profile similar to placebo.
• Low incidence of LVEF <50% (no occurrences associated with serious heart failure) and new-onset AF (1.9%) was observed, comparable to placebo (2%) and metoprolol (3.4%).
• Aficamten is an investigational drug candidate under regulatory review in the U.S. with a PDUFA target action date of December 26, 2025. It also has Breakthrough Therapy Designation from the U.S. FDA and China NMPA.

Sentiment

Score: 9

Explanation: The data presented for aficamten is overwhelmingly positive, demonstrating superiority over standard-of-care in key cardiac metrics, a favorable safety profile, and sustained long-term benefits. This strengthens its position for regulatory approval and commercial success in a significant market.

Positives

• Aficamten demonstrated superiority over metoprolol (standard-of-care) in improving cardiac structure and function, including diastolic function and reducing LVOT obstruction.
• Significant decrease in maximal wall thickness (-1.01 mm, p=0.015) in aficamten-treated patients compared to metoprolol.
• The annual incidence rate of new-onset atrial fibrillation (1.5%) with aficamten is consistent with expected rates in both HCM patients and healthy individuals, suggesting no increased risk.
• Long-term treatment with aficamten showed sustained hemodynamic and clinical benefits, including significant reductions in LVOT obstruction and improved NYHA Functional Class (69% at Week 12, 93% at Week 96).
• Aficamten was well-tolerated across multiple trials with an adverse event profile similar to placebo, and a low incidence of LVEF <50% and new-onset AF.
• No permanent discontinuations related to aficamten treatment were observed in the integrated safety analysis.
• Improvements in symptom burden, KCCQ-CSS, and cardiac biomarkers (NT-proBNP, high-sensitivity cardiac troponin I) were significant and sustained.

Negatives

• Reduction in left ventricular mass index (LVMI) was not significantly different comparing aficamten to metoprolol.
• One patient (1.1%) treated with aficamten experienced transient LVEF <50% without heart failure or treatment interruption in MAPLE-HCM.
• One patient (0.3%) in FOREST-HCM terminated treatment due to ischemic colitis, though it was determined not to be related to aficamten.
• Dose down-titration occurred in 10 (3.4%) patients in FOREST-HCM based on site-read LVEF <50%, though none were corroborated by the core lab or associated with serious heart failure.

Risks

• Potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of drug candidates.
• Drug candidates may have adverse side effects or inadequate therapeutic efficacy.
• FDA or foreign regulatory agencies may delay or limit the ability to conduct clinical trials.
• Inability to obtain or maintain patent or trade secret protection for intellectual property.
• Standards of care may change, rendering drug candidates obsolete.
• Competitive products or alternative therapies may be developed by others for the treatment of targeted indications.

Future Outlook

Aficamten is currently under regulatory review by the U.S. FDA with a PDUFA target action date of December 26, 2025, and also by the European Medicines Agency (EMA) and China NMPA (with Priority Review). The company is readying for potential regulatory approvals and commercialization of aficamten. Ongoing clinical trials include ACACIA-HCM (non-obstructive HCM) and CEDAR-HCM (pediatric oHCM).

Management Comments

• "The echocardiographic results from MAPLE-HCM elaborate on the superiority of aficamten compared to the current standard-of-care metoprolol as was previously reported in the primary efficacy analyses." Fady I. Malik, M.D., Ph.D., Cytokinetics Executive Vice President of Research & Development.
• "The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of aficamten, including as has been observed with a real-world dosing strategy." Fady I. Malik, M.D., Ph.D., Cytokinetics Executive Vice President of Research & Development.
• Authors concluded that "long-term treatment with aficamten did not appear to increase the risk for AF, nor did the presence of AF negatively impact clinical outcomes."

Industry Context

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disorder affecting an estimated 400,000-800,000 undiagnosed patients in the U.S., with two-thirds having obstructive HCM. Patients are at high risk of cardiovascular complications including atrial fibrillation, stroke, and sudden cardiac death. Aficamten, as a cardiac myosin inhibitor, targets the underlying myocardial hypercontractility, offering a potentially superior treatment option compared to current standard-of-care like metoprolol, which primarily manages symptoms. The positive data positions aficamten favorably in a market with significant unmet medical needs.

Comparison to Industry Standards

• Aficamten demonstrated superiority over metoprolol, a current standard-of-care beta-blocker, in improving cardiac structure and function in MAPLE-HCM.
• The observed annual incidence rate of new-onset atrial fibrillation (1.5%) with aficamten is consistent with expected rates from validated prediction models in HCM patients (HCM-AF: 3.6% per year) and healthy individuals (CHARGE-AF: 1.4% per year), suggesting a favorable safety profile regarding AF risk compared to the natural progression of the disease.
• The adverse event profile of aficamten in an integrated safety analysis was similar to placebo, indicating a strong tolerability profile compared to non-active treatment.

Stakeholder Impact

• Shareholders: Positive clinical data and progress towards regulatory approval could increase shareholder value and confidence in the company's pipeline.
• Patients with HCM: Aficamten offers a potentially superior and safer treatment option for a debilitating disease, improving cardiac function and reducing symptoms.
• Healthcare Providers: New data provides stronger evidence for aficamten's efficacy and safety, potentially influencing prescribing patterns upon approval.

Next Steps

• Cytokinetics will host an investor webcast on September 2, 2025, to discuss the data.
• Continued regulatory review of aficamten's New Drug Application (NDA) by the U.S. FDA, with a PDUFA target action date of December 26, 2025.
• Continued regulatory review by the European Medicines Agency (EMA) and China NMPA.
• Ongoing clinical trials for aficamten in non-obstructive HCM (ACACIA-HCM) and pediatric oHCM (CEDAR-HCM).
• Potential regulatory approvals and commercialization of aficamten.

Key Dates

Recommendation

The new clinical data for aficamten is highly positive, demonstrating superiority over the current standard-of-care in critical cardiac function and structural improvements, alongside a favorable long-term safety profile, particularly regarding atrial fibrillation risk. This significantly de-risks the regulatory approval process, especially with a PDUFA date approaching in December 2025, and strengthens the commercial potential of a drug targeting a large, underserved patient population. The consistent positive results across multiple trials and the Breakthrough Therapy Designation further underscore its market potential and competitive advantage.

Keywords

Cytokinetics, aficamten, hypertrophic cardiomyopathy, HCM, cardiac myosin inhibitor, MAPLE-HCM, FOREST-HCM, European Society of Cardiology Congress, atrial fibrillation, cardiac structure, cardiac function, LVOT obstruction, FDA, NDA, PDUFA, biopharmaceutical, cardiovascular